Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging.
We have characterized the biodistribution and dosimetry of (18)F-3'-F-6-OH-BTA1 ((18)F-GE067), a newly developed radioligand to visualize and quantify amyloid burden, in healthy elderly human subjects.Six subjects (5 men and 1 woman; age range, 51-74 y) underwent dynamic whole-body PET/CT for 6...
| Main Authors: | , , , , , , , |
|---|---|
| Formato: | Journal article |
| Idioma: | English |
| Publicado em: |
2009
|
| _version_ | 1826303890601017344 |
|---|---|
| author | Koole, M Lewis, D Buckley, C Nelissen, N Vandenbulcke, M Brooks, D Vandenberghe, R Van Laere, K |
| author_facet | Koole, M Lewis, D Buckley, C Nelissen, N Vandenbulcke, M Brooks, D Vandenberghe, R Van Laere, K |
| author_sort | Koole, M |
| collection | OXFORD |
| description | We have characterized the biodistribution and dosimetry of (18)F-3'-F-6-OH-BTA1 ((18)F-GE067), a newly developed radioligand to visualize and quantify amyloid burden, in healthy elderly human subjects.Six subjects (5 men and 1 woman; age range, 51-74 y) underwent dynamic whole-body PET/CT for 6 h after a bolus injection of (18)F-GE067. Source organs were delineated on PET/CT. Individual organ doses and effective doses were determined.No adverse events or clinically significant changes were observed. (18)F-GE067 is excreted predominantly through the hepatobiliary system. The gallbladder, upper large intestine, and small intestine are the organs with the highest absorbed dose (average, 287, 173, and 155 microGy/MBq, respectively). The mean effective dose was 33.8 +/- 3.4 microSv/MBq, a dose comparable to that of many other (18)F-labeled radiopharmaceuticals.The estimated effective dose of (18)F-GE067 for PET amyloid imaging was acceptable (class II-b defined by the World Health Organization), and relatively low variability between subjects was observed. |
| first_indexed | 2024-03-07T06:09:34Z |
| format | Journal article |
| id | oxford-uuid:ef0307fb-db65-4d40-8010-82ee066e2088 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:09:34Z |
| publishDate | 2009 |
| record_format | dspace |
| spelling | oxford-uuid:ef0307fb-db65-4d40-8010-82ee066e20882022-03-27T11:37:09ZWhole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ef0307fb-db65-4d40-8010-82ee066e2088EnglishSymplectic Elements at Oxford2009Koole, MLewis, DBuckley, CNelissen, NVandenbulcke, MBrooks, DVandenberghe, RVan Laere, KWe have characterized the biodistribution and dosimetry of (18)F-3'-F-6-OH-BTA1 ((18)F-GE067), a newly developed radioligand to visualize and quantify amyloid burden, in healthy elderly human subjects.Six subjects (5 men and 1 woman; age range, 51-74 y) underwent dynamic whole-body PET/CT for 6 h after a bolus injection of (18)F-GE067. Source organs were delineated on PET/CT. Individual organ doses and effective doses were determined.No adverse events or clinically significant changes were observed. (18)F-GE067 is excreted predominantly through the hepatobiliary system. The gallbladder, upper large intestine, and small intestine are the organs with the highest absorbed dose (average, 287, 173, and 155 microGy/MBq, respectively). The mean effective dose was 33.8 +/- 3.4 microSv/MBq, a dose comparable to that of many other (18)F-labeled radiopharmaceuticals.The estimated effective dose of (18)F-GE067 for PET amyloid imaging was acceptable (class II-b defined by the World Health Organization), and relatively low variability between subjects was observed. |
| spellingShingle | Koole, M Lewis, D Buckley, C Nelissen, N Vandenbulcke, M Brooks, D Vandenberghe, R Van Laere, K Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. |
| title | Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. |
| title_full | Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. |
| title_fullStr | Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. |
| title_full_unstemmed | Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. |
| title_short | Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. |
| title_sort | whole body biodistribution and radiation dosimetry of 18f ge067 a radioligand for in vivo brain amyloid imaging |
| work_keys_str_mv | AT koolem wholebodybiodistributionandradiationdosimetryof18fge067aradioligandforinvivobrainamyloidimaging AT lewisd wholebodybiodistributionandradiationdosimetryof18fge067aradioligandforinvivobrainamyloidimaging AT buckleyc wholebodybiodistributionandradiationdosimetryof18fge067aradioligandforinvivobrainamyloidimaging AT nelissenn wholebodybiodistributionandradiationdosimetryof18fge067aradioligandforinvivobrainamyloidimaging AT vandenbulckem wholebodybiodistributionandradiationdosimetryof18fge067aradioligandforinvivobrainamyloidimaging AT brooksd wholebodybiodistributionandradiationdosimetryof18fge067aradioligandforinvivobrainamyloidimaging AT vandenbergher wholebodybiodistributionandradiationdosimetryof18fge067aradioligandforinvivobrainamyloidimaging AT vanlaerek wholebodybiodistributionandradiationdosimetryof18fge067aradioligandforinvivobrainamyloidimaging |